Fibroblast growth factor 21 (FGF21), which is mainly produced and secreted by the liver [1, 2] , plays an important role in glucose and lipid metabolism [3] [4] [5] . It has anti-inflammatory, anti-diabetic and hypolipidaemic effects in animal studies [1, 2] . However, in clinical studies, circulating FGF21 levels are often elevated in obesity, dyslipidemia, insulin resistance, metabolic syndrome, type 2 diabetes (T2D), nonalcoholic fatty liver disease and coronary artery disease, and has been identified as a potential biomarker for the early detection of cardiometabolic dysfunction [1, 2] . Elevated FGF21 levels in this context may be due to FGF21 resistance resulting from impaired FGF21 signaling or compensatory responses to the underlying metabolic stress [1, 2] .
Elevated circulating FGF21 levels have been reported to be associated with coronary heart disease (CHD) [6] , carotid atherosclerosis [7] , and acute myocardial infarction [8] . In T2D patients, elevated FGF21 levels can predict the development of incident total cardiovascular disease (CVD) events [9] . However, it is unknown whether circulating FGF21 levels can predict CVD events in statin-treated patients. This is particularly important given that statins are widely used for CVD prevention, and hepatic FGF21 expression is repressed in statin-treated mice [10] .
The Treating to New Targets (TNT) trial was a double-blind randomized controlled trial [11] . Briefly, 10,001 patients with stable coronary artery disease (CAD) and an low-density lipoprotein (LDL) cholesterol level off-therapy of 3.4-6.5 mmol/L (130-250 mg/dL), decreasing to b3.4 mmol/L (130 mg/dL) after an 8-week run-in period on atorvastatin 10 mg/day, were randomized to 10 mg or 80 mg/day of atorvastatin with a median follow-up period of 4.9 years [11] . The mean LDL cholesterol during follow-up was 2.6 mmol/L (101 mg/dL) in the 10 mg/day group and 2.0 mmol/L (77 mg/dL) in the 80 mg/day group. The primary endpoint of total major cardiovascular events (MCVEs) occurred in 10.9% of patients in the 10 mg group and 8.7% of patients in the 80 mg group (hazards ratio [HR] 0.78, 95% CI 0.69-0.89, P b 0.001) [11] .
In the present study, we asked whether plasma FGF21 levels at the time of randomization (after the 8-week atorvastatin 10 mg run-in period) predict MCVEs in participants from the TNT trial. We also assessed the effect of higher dose of atorvastatin on plasma FGF21 levels at one year after randomization, and whether plasma FGF21 levels at one year predict subsequent risk of MCVEs. The underlying rationale of the study is to provide an insight into whether FGF21 is a CVD risk biomarker in statin-treated patients.
Material and Methods

Study Population
The study design and results of the TNT trial have been published [11] . Patients with stable CAD were randomized to two doses of atorvastatin (either 10 or 80 mg daily). Participants were recruited in 14 countries and randomization occurred between July 1998 and December 1999 [11] . The primary endpoint was MCVE, a composite of (i) CHD death, (ii) nonfatal, non-procedure-related myocardial infarction, (iii) resuscitated cardiac arrest, and (iv) fatal or nonfatal stroke. All patients gave written informed consent. The study was approved by local research ethics committees or institutional review boards at each center and was performed in accordance with the Helsinki Declaration.
Among 10,001 patients, 9960 had blood samples available at the time of randomization. Plasma FGF21 levels were measured in a random sub-sample of 2032 participants, in which informed consent was obtained for measuring non-lipid biomarkers (in addition to that originally collected for the primary study).
FGF21 Level Measurement
Blood samples were collected in 10-mL EDTA Vacutainer (BD, Franklin Lakes, New Jersey) venous blood collection tubes using standard phlebotomy practices. Immediately after collection, tubes were gently inverted six times, and centrifuged at 2000 ×g (10 min). Plasma samples were transferred into 8-mL freezer vials, frozen (−70°C), shipped on dry ice, and thawed for biomarker analysis. FGF21 levels were measured from stored plasma samples obtained at randomization (after the 8-week atorvastatin 10 mg run-in period) and again one year after randomization. FGF21 levels were measured using ELISA kits from the Antibody and Immunoassay Services, University of Hong Kong, Hong Kong (www.antibody.hku.hk) as described previously [9, 12] . Briefly 60 μL of plasma sample was diluted 1:1 (v:v) with assay diluent and analyzed together with quality controls as per the manufacturer's instruction. The intra-assay and inter-assay CVs were b6%. All samples were analyzed masked for participant identity, treatment allocation and time-point.
Statistical Analysis
Statistical analysis was performed using SPSS 24 (IBM, Armonk, NY) or STATA 14.0 (StataCorp, College Station, TX). Data are presented as mean ± SD or n (percentage). Comparisons of participant characteristics at the time of randomization between treatment groups or outcomes were performed using a chi-square test for categorical variables, and an independent t-test for continuous variables. For nonnormally-distributed variables, data were presented as median (interquartile range) and compared using Wilcoxon rank sum test. Treatment allocation, age, sex, and other variables that showed a trend of difference (P b 0.1) in either treatment group were used as covariates in subsequent multiple Cox regression analyses.
Associations of baseline FGF21 levels with incident MCVE over the follow-up period was assessed using Cox proportional hazards regression analysis. In this analysis, for each participant that had an event, the time to event (in days) was taken as that between the randomization date and the date of the visit at which the earliest event was ascertained. For participants who remained event-free, the follow-up time was censored at last visit or last day known to be alive, whichever was later. For subjects who died, follow-up time was censored at their death date. As plasma FGF21 levels were highly skewed, data were lntransformed in the Cox regression analyses to prevent unstable estimates of effects since extreme values may have undue influence on the estimate of the regression coefficient. Associations of FGF21 levels and change in FGF21 levels at 1-year post-randomization with subsequently incident MCVE were analyzed similarly while excluding patients with any prior event (or censored) during the first year postrandomization. Survivals were estimated by the Kaplan-Meier method and compared by the log-rank test. The proportional hazards assumption was checked using Schoenfeld residuals and no significant violation was found. In all analyses, we also investigated whether there was an interaction by treatment allocation. P for interaction was estimated by including the interaction term in the regression models in the full sample after adjustment for the main effects of the covariates. The incremental value of the addition of ln-transformed FGF21 levels in the Cox regression model was assessed by the change in Harrell's C-statistic using a method adapted for survival models [13] . The goodness of fit of the models was assessed using the Gronnesby and Borgan test [14] . Net reclassification improvement (NRI) were also assessed as described previously [15] . As the NRI method is highly sensitive to the chosen cut-points of risk and there are no pre-specified cut-points that can be applied to the outcome appropriately, the category-free NRI (NRI N 0) approach was utilized with both "event NRI" and "nonevent NRI" calculated [16] . NRI was calculated using a macro in SAS 9.4 (SAS Institute, Cary, NC) [17] . A two-tailed P b 0.05 was considered statistically significant. In all the analyses, participants with missing data were excluded.
Results
Clinical Characteristics
As shown in Supplementary Table 1, there were no significant difference in age, sex, body mass index (BMI) and percentage of participants receiving high-dose statin treatment between these 2032 participants and the remaining 7928 participants (all P N 0.10). Among these 2032 participants, results from 36 participants (1.8%) were excluded from further analysis as the FGF21 levels were below the assay limit of detection (b8.69 pg/mL). Therefore, a total of 1996 participants were included in the analysis of plasma FGF21 levels at the time of randomization. As shown in Supplementary Table 2, there were no significant difference in age, sex, BMI, percentage of participants receiving highdose statin treatment and other clinical characteristics between these 1996 participants and the excluded 36 participants, except that excluded participants were more likely to be current smokers and had higher total cholesterol than those not excluded (P = 0.039 and 0.031, respectively). Table 1 shows the clinical characteristics of the 1996 participants at the time of randomization. Clinical characteristics were similar in the groups randomized to remain on 10 mg atorvastatin (n = 1012, 50.7%) and to receive atorvastatin 80 mg (n = 984, 49.3%). Within the same treatment group, participants who developed an MCVE were more likely to be older, and have hypertension, diabetes and higher white blood cell count at time of randomization, compared to participants who did not developed an MCVE. In the 10 mg atorvastatin group, participants who developed an MCVE were also less likely to be Caucasian, and more likely to be a current smoker, have lower highdensity lipoprotein (HDL) cholesterol and have higher triglyceride levels than those who did not. In the 80 mg atorvastatin group, participants who developed an MCVE were also more likely to have a higher BMI, and blood urea nitrogen levels.
FGF21 Levels at Randomization and Risk of MCVE
At randomization plasma FGF21 levels were significantly higher in participants with versus without incident MCVE (median [interquartile range]: 253.5 [164.3-398.5] vs 204.6 [127.0-316.9] respectively, P b 0.001). Similar significant differences was present within the 10 mg and 80 mg atorvastatin group (Table 1 ). Fig. 1A shows the KaplanMeier cumulative curves for incident MCVE over time across FGF21 level tertiles at randomization. Higher FGF21 tertiles at randomization had a higher risk of incident MCVE (log-rank test P b 0.001). As shown in Table 2 , the association of ln-transformed FGF21 levels with incident MCVE was significant after adjusting for confounding variables, including treatment allocation, age, sex, Caucasian race, BMI, smoking status, hypertension, diabetes, HDL-cholesterol, triglycerides, blood urea nitrogen, and white blood cell count at baseline (P = 0.019). Similar significant results were obtained when continuous FGF21 levels were assessed as a categorical tertile variable. No significant treatment interaction was found. In a sensitivity analysis with exclusion of participants with FGF21 levels in the top and bottom 5% (Supplementary Table 3 ), higher FGF21 levels were still associated with higher risk of incident MCVE after adjusting for confounding variables (P = 0.004 for lntransformed FGF21 levels and P = 0.020 for FGF21 tertiles).
Effect of High and Low Dose Atorvastatin on Plasma FGF21 Levels over One Year
Among these 1996 participants, FGF21 levels were also measured at one year after randomization in 1849 participants, of whom 14 participants (0.8%) were excluded from analysis due to FGF21 levels below the assay limit. Therefore, a total of 1835 participants were included in the analysis of FGF21 levels at one year. Table 3 shows the FGF21 levels at randomization and 1-year post-randomization, as well as the absolute and relative changes in FGF21 levels over one year by treatment groups and status of incident MCVE. At the time of randomization, there was no significant difference in FGF21 levels between treatment groups (P = 0.83). However, at 1-year post-randomization, FGF21 levels in the 80 mg atorvastatin group, were significantly lower than in the 10 mg atorvastatin group (P = 0.006). FGF21 levels decreased more significantly over time in the 80 mg atorvastatin group (P = 0.001), compared to the 10 mg atorvastatin group (P = 0.034), with both absolute and relative decreases in FGF21 levels being approximately twice that with 80 mg atorvastatin than with 10 mg atorvastatin (both P = 0.011). Although, in both treatment groups, the FGF21 levels at randomization and at 1-year post-randomization were significantly higher in patients with incident MCVE, compared to those without MCVE, the change in FGF21 levels did not differ significantly between participants with and without incident MCVE in each treatment group. Fig. 1B shows the Kaplan-Meier cumulative curves for incident MCVE over time across FGF21 tertiles at 1-year post-randomization. Participants in the higher FGF21 tertiles at 1-year post-randomization had a higher subsequent risk of incident MCVE (log-rank test P b 0.001). As shown in Table 4 , the association of ln-transformed FGF21 levels at one year with subsequent incident MCVE was significant after adjusting for confounding variables (P = 0.009). Similar significant results were obtained when continuous FGF21 levels were assessed as a categorical tertile variable. No significant treatment interaction was found. However, when assessing the changes in FGF21 levels over 1-year post-randomization as continuous variables, a larger relative change in FGF21 levels was associated with higher subsequent risk of MCVE (P = 0.002, Supplementary Table 4) . However, such significant association was not found when assessing absolute changes in FGF21 level, or when assessing the changes as categorical variables (Supplementary Fig. 1 
FGF21 Levels at One Year after Randomization and Subsequent Risk of MCVE
and Supplementary Tables 4 & 5).
Incremental Value of FGF21 Levels for Risk Prediction
Addition of the FGF21 levels to a model adjusted for treatment allocation, age, sex, Caucasian race, BMI, smoking status, hypertension, diabetes, HDL-cholesterol, triglycerides, blood urea nitrogen, and white blood cell count only modestly increased the C-statistic, with a borderline non-significance P = 0.082 (Supplementary Table 6 ). When assessing reclassification using the category-free NRI(N0), addition of FGF21 levels at randomization to a model with traditional cardiovascular risk factors significantly increased the NRI(N0) of 20.9% for incident MCVE (Table 5 ). This was the result of both correct upward reclassification of those with events (net gain in reclassification of 16.4%), and from correct downward reclassification of nonevents (net gain in reclassification of 4.5%). Similar results were obtained when assessing the incremental value of FGF21 levels at 1-year post-randomization.
Discussion
The present findings support FGF21 as a CVD biomarker in high risk patients, even on statins. This is the first study to investigate the association of plasma FGF21 levels and CVD events in a clinical trial of statintreated subjects. Higher plasma FGF21 levels were associated with higher CVD risk in statin-treated patients. Plasma FGF21 levels were also decreased in the 80 mg atorvastatin group compared to the 10 mg atorvastatin group, but the changes in FGF21 levels over 1-year post-randomization were not robustly related to subsequent CVD risk over a median of 3.9 years, it follows that statin-associated FGF21 reduction do not play a major role in statin-mediated CVD risk reduction.
The role of FGF21 in CVD has been reported in earlier pre-clinical studies. Cardiomyocytes have been found to express and release FGF21 in an autocrine-paracrine manner [18, 19] . FGF21's antiinflammatory, anti-oxidative and anti-apoptotic properties of FGF21 also protect against CVD events, including cardiac hypertrophy and myocardial infarction, in mice [18] [19] [20] [21] . Global FGF21-knockout mice are also more likely to develop cardiac hypertrophy than wild-type mice [18] .
Despite exhibiting cardioprotective effects in cell culture and preclinical animal studies, elevated circulating FGF21 levels have been reported in patients with CHD [22] , carotid atherosclerosis [7, 23] , subclinical atherosclerosis [24] , and acute myocardial infarction [8] . These observations could be due to the presence of FGF21 resistance in these conditions. In rodent models, cardiomyocytes can secrete FGF21 in response to global cardiac ischemia [19] . However, some human studies have shown no associations between FGF21 levels and CVD [25, 26] . Nevertheless, these studies are limited by having a cross-sectional design and relatively small sample size (n b 420).
The predictive value of FGF21 levels for CV-related adverse events has been explored in earlier prospective studies. In a study of 87 T2D patients, above median FGF21 levels at baseline predicted higher CV morbidity and mortality, but not total mortality, over 2 years follow-up [27] . In another study of 1668 CAD patients, both lower and higher FGF21 levels predicted all-cause and CVD mortality over a median of 4.9 years follow-up, in which the smallest HR was associated with second quartile of FGF21 levels [28] . In 253 Chinese subjects that underwent a coronary angiography, serum FGF21 levels were independently associated with prevalent CAD [6] and left ventricular systolic dysfunction at baseline, and higher risk of cardiac death over 5 years [29] . In the same cohort of subjects, higher serum FGF21 levels predicted development of major adverse cardiovascular events in 169 patients with CAD at baseline [30] . In another study of 3528 T2D patients, the optimal cut-off value of serum FGF21 levels at baseline was 206 pg/mL, levels above which predicted incident CHD over a median follow-up of 3.8 years [31] . In our previous study of 9697 T2D patients not on statin at baseline, higher plasma FGF21 levels predicted CVD events over 5 years follow-up [9] . When considered together, these results support FGF21 levels as a potential CVD biomarker, though few participants were on statin therapy.
In the present study, higher plasma FGF21 levels at randomization were associated with a higher risk of incident MCVE after adjusting for confounding variables including demographics and traditional CVD risk factors. Similar results were obtained with FGF21 levels assessed as either a continuous or categorical (tertile) variable. Similar results were obtained when subjects with FGF21 levels in the top or bottom 5% were excluded in the sensitivity analysis, or based on FGF21 levels at 1-year post-randomization. This supports the robustness of our findings. The present larger study extends previous findings by showing that plasma FGF21 levels can predict CVD events in high-CVD risk statin-treated patients with stable CHD. Moreover, as no significant treatment interaction was found in all the analyses, it follows that the association of FGF21 levels with MCVEs did not differ significantly between low-and high-dose atorvastatin. This also suggests that FGF21- based therapies may confer cardioprotection in statin-treated patients, which merits study. Statins are commonly used for CVD prevention. In the present study, FGF21 levels decreased significantly after 1-year of atorvastatin, and the decreases in FGF21 levels were twice that with high-dose atorvastatin than with low-dose atorvastatin. We speculate this reduction could be due to reduced FGF21 resistance, but underlying mechanisms of statin-associated reduction in FGF21 levels are not clear. FGF21 is mainly produced and secreted by the liver. Notably, liver enzymes can be elevated by statins [32] , in keeping with altered liver homeostasis, which may affect FGF21 production. A recent meta-analysis of controlled clinical trials has shown reduction of plasma free fatty acids (FFAs) by atorvastatin [33] , and FFAs can stimulate FGF21 expression in vitro [34] . Short-term simvastatin suppresses hepatic FGF21 expression and reduces circulating FGF21 levels in mice as well as FGF21 expression in mouse primary hepatocytes [10] . All these findings are consistent with our clinical study results.
In this study, we also assessed the relationship of changes in FGF21 levels over 1-year post-randomization with subsequent risk of MCVEs and found no robustly significant associations. This suggests that FGF21 may not play a major causal role in the development of MCVEs over the short-term, even though its circulating levels can predict in future MCVEs. However, it should be noted that the change in FGF21 levels found was small compared to the supraphysiological doses that were used in two proof-of-concept clinical trials of the FGF21 variants, LY2405319 and PF-05231023 [35, 36] . In those trials, treatment with FGF21 variants improved body weight, lipid and adiponectin levels in overweight/obese T2D patients [35, 36] . Further studies are warranted to investigate the effects of these FGF21 variants on CVD risk reduction.
Our study suggests FGF21 may be a CVD biomarker with potential prognostic value as assessed by its ability to improve net reclassification. Although FGF21 levels did not result in a significant change in the Cstatistic, the C-statistic is a less sensitive measure than the NRI(N0) approach [15] . Further studies are needed to compare the prognostic value of FGF21 with other biomarkers, especially NT-proBNP, as well as their prognostic ability with considered in combination.
The present study has several strengths. It takes advantage of the large sample size, well-defined inclusion and exclusion criteria, the well-characterized double-blinded parallel study design and the uniform follow-up of the TNT trial, in which all patients took low-dose atorvastatin for 8 weeks pre-randomization. There are also some limitations. Participants were not further stratified into subgroups based on the number of coronary arteries involved or degree of stenosis, however another cross-sectional study found no significant difference in plasma FGF21 levels among CHD patients by numbers of stenosed coronary arteries involved [26] . The present study was a post-hoc analysis of the TNT trial, though all analyses were performed after pre-stating ⁎ Data are expressed as HR (95% CI) in terms of per SD (0.8016) increase in ln-transformed levels. † Data were adjusted for treatment allocation, age, sex, Caucasian race, body mass index, smoking status, hypertension, diabetes, high-density lipoprotein cholesterol, triglycerides, blood urea nitrogen, and white blood cell count at baseline. Four patients (two with MCVE events) were excluded from adjusted model due to missing baseline body mass index for 3 subjects and missing baseline high-density lipoprotein cholesterol and triglycerides for 1 subject. ⁎ P value for the difference in FGF21 levels between time of randomization and 1-year post-randomization within each group using Wilcoxon signed rank test. † P value for patients who experienced MCVEs versus those who did not in both treatment groups using Wilcoxon rank sum test. ‡ P value for patients randomized to remain on 10 mg atorvastatin versus patients up-titrated to 80 mg atorvastatin using Wilcoxon rank sum test.
hypotheses and as per a pre-specified statistical analysis plan. Plasma samples used for FGF21 measurement were stored at −80°C for N15 years, and we cannot exclude the possibility of confounding effects due to long-term sample storage. However, in our previous pilot study, serum FGF21 levels were stable after 1-6 freeze-thaw cycles a CV of 8.1% [12] . In an exploratory analysis, we did not find any correlation between FGF21 levels and length of sample storage (Spearman correlation coefficient = 0.008, P = 0.72). During the FGF21 ELISA assay, not all samples from the same participant were analyzed in the same analytical run. However, the intra-assay and inter-assay CVs were small, and the potential bias should be random in direction and weaken the observed association.
In summary, our TNT trial based study has demonstrated that plasma FGF21 levels can predict incident MCVE over 5 years in statintreated patients with stable CHD. Our findings support the use of FGF21 as a potential CVD risk biomarker in high-risk, statin-treated patients. O. is the guarantor of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data. All Authors approved the final version of the manuscript.
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